Redeye returns with a more detailed take on the Q3 report. The beat compared to our estimates strengthens our confidence in the equity story, but we do not make any meaningful estimate changes. We believe investors have started to realise there is no need for a capital raise, which has recently put pressure on the share price.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/